logo-loader
RNS
viewTissue Regenix Group PLC

Tissue Regenix Group - Publication of circular and notice of GM

RNS Number : 9069N
Tissue Regenix Group PLC
26 May 2020
 

26 May 2020

Tissue Regenix Group plc

("Tissue Regenix", the "Group" or the "Company")

 

Publication of circular and notice of General Meeting

 

Tissue Regenix announces that a circular containing further information on its recent fundraise (the "Circular") was posted to Shareholders on Friday 22 May. The Circular also contains a notice of General Meeting (the "General Meeting") and accompanying form of proxy.

 

The General Meeting will be held at the offices of Squire Patton Boggs (UK) LLP, 6 Wellington Place, Leeds at 12 noon on 9 June 2020.

 

The UK Government passed into law mandatory measures in order to reduce the transmission of COVID-19. These mandatory measures prohibit, amongst other things, individuals engaging in non-essential travel and public gatherings of more than two people, save where the gathering is essential for work purposes (the "Stay at Home Measures").

 

The Company is required to hold the General Meeting in order to implement the planned fundraise. However the Stay at Home Measures will significantly restrict our ability to follow a standard shareholder meeting format. In order to ensure shareholders can comply with the Stay at Home Measures the Board has concluded that shareholders should not plan to attend the General Meeting in person. It is currently intended that the General Meeting will be held with only the minimum number of shareholders present as required to form a quorum under the Company's Articles of Association, and who are essential for the business of the General Meeting to be conducted.

 

The results of the votes on the proposed resolutions will be announced in the normal way as soon as practicable after the conclusion of the General Meeting.

 

Having regard to their own safety and that of others, shareholders are respectfully asked to comply with the Stay at Home Measures and not make plans to attend the General Meeting. To ensure the safety of the limited number of people whose attendance is essential, the Company will not be able to allow other shareholders to gain access to the General Meeting on the day. Given the restrictions on travel and as to how the meeting itself may be conducted, shareholders are strongly encouraged to exercise their right to vote and to submit a proxy as early as possible.

 

The Circular, notice of General Meeting and accompanying form of proxy, are also available on the Company's website, www.tissueregenix.com, in accordance with AIM Rule 20.

For more information:

 

Tissue Regenix Group plc

Caitlin Pearson, Head of Communications  

Tel: 0330 430 3073 / 07920272441

 

 

Stifel Nicolaus Europe Limited (Nominated Adviser and Broker)

Jonathan Senior  / Ben Maddison / Alex Price

Tel:  0207 710 7600

 

 

 

FTI Consulting 

Simon Conway / Victoria Foster Mitchell / Mary Whittow

Tel: 0203 727 1000

About Tissue Regenix

Tissue Regenix is a leading medical devices company in the field of regenerative medicine. Tissue Regenix was formed in 2006 when it was spun-out from the University of Leeds, UK. The Company's patented decellularisation ('dCELL®') technology removes DNA and other cellular material from animal and human soft tissue leaving an acellular tissue scaffold which is not rejected by the patient's body and can then be used to repair diseased or worn out body parts. Current applications address many critical clinical needs such as sports medicine, heart valve replacement and wound care.

 

In November 2012 Tissue Regenix Group plc set up a subsidiary company in the United States - 'Tissue Regenix Wound Care Inc.' and January 2016 saw the establishment of joint venture GBM-V, a multi- tissue bank based in Rostock, Germany.

 

In August 2017 Tissue Regenix acquired CellRight Technologies®, a biotech company that specialises in regenerative medicine and is dedicated to the development of innovative osteoinductive and wound care scaffolds that enhance healing opportunities of defects created by trauma and disease. CellRight's human osteobiologics may be used in spine, trauma, general orthopedic, foot & ankle, dental, and sports medicine surgical procedures.

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
NOGAFMATMTTTMAM

Quick facts: Tissue Regenix Group PLC

Price: 0.33

Market: AIM
Market Cap: £23.21 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Tissue Regenix "advancing on many fronts" says CEO after SurgiPure FDA clearance

Antony Odell, chief executive at Tissue Regenix (LON:TRX), talks to Proactive Investors about the US FDA clearance for SurgiPure XD, a skin graft for hernias derived from pig tissue. The group, which already has experience of commercialising products in the US, is planning a commercial...

on 03/09/2016